Oncotelic Therapeutics, Inc. (OTLC)
OTCMKTS · Delayed Price · Currency is USD
0.0501
-0.0032 (-6.07%)
Aug 26, 2025, 3:46 PM EDT
Oncotelic Therapeutics Employees
Oncotelic Therapeutics had 26 employees as of December 31, 2024. The number of employees increased by 4 or 18.18% compared to the previous year.
Employees
26
Change (1Y)
4
Growth (1Y)
18.18%
Revenue / Employee
n/a
Profits / Employee
-$151,011
Market Cap
23.18M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 26 | 4 | 18.18% |
Dec 31, 2023 | 22 | 0 | - |
Dec 31, 2022 | 22 | 6 | 37.50% |
Dec 31, 2021 | 16 | 0 | - |
Dec 31, 2020 | 16 | 3 | 23.08% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
Tian'an Technology Group | 8 |
Glass House Brands | 374 |
Elite Pharmaceuticals | 68 |
CytoDyn | 13 |
American Oncology Network | 1,914 |
Northwest Biotherapeutics | 25 |
Silence Therapeutics | 116 |
Oncotelic Therapeutics News
- 22 days ago - OTCQB Venture Virtual Investor Conference Agenda Announced for August 7th - GlobeNewsWire
- 5 weeks ago - SAPU Bioscience Highlights Peer‑Reviewed Publication Linking TGFB2 to Survival in Younger Pancreatic Cancer Patients - GlobeNewsWire
- 5 weeks ago - Oncotelic Therapeutics Highlights Peer‑Reviewed Publication Linking TGFB2 to Survival in Younger Pancreatic Cancer Patients - GlobeNewsWire
- 2 months ago - Oncotelic Therapeutics Announces Publication of Landmark Study on TGFB2 Gene Methylation as a Positive Prognostic Marker in Pancreatic Cancer - GlobeNewsWire
- 4 months ago - Oncotelic CEO Vuong Trieu to Present Innovative "Deciparticles" Platform at IDDST-Europe 2025 Conference in Stockholm - GlobeNewsWire
- 4 months ago - Oncotelic Therapeutics Reports FY 2024 Highlights and FY 2024 Earnings Compared to FY 2023 - GlobeNewsWire
- 5 months ago - Oncotelic Therapeutics Publishes New Research Demonstrating Positive Prognostic Impact of Methylated TGFB2 and MGMT in Adult Glioblastoma Patients, Introduces Interactive PDAOAI - GlobeNewsWire
- 5 months ago - Oncotelic Therapeutics Announces Successful Completion of Phase 1 Trial of OT-101 and IL-2, Highlights Findings at SWCR 2025 Conference - GlobeNewsWire